J. Schafer

发表

Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix.

A. D. De Groot, B. Jesdale, J. Schafer, 1998, Vaccine.

Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer.

K. Hunt, M. Yi, A. Sahin, 2016, The American journal of pathology.

Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.

K. Rezvani, E. Shpall, Dean Anthony Lee, 2017, Blood.

Trace Evidence: Identifying Natural Cancer Killers After the Crime

Dean Anthony Lee, J. Schafer, 2015, EBioMedicine.

Natural killer cells for antiviral therapy

David M. Smith, S. Paust, J. Schafer, 2023, Science Translational Medicine.

A LICENSE TO KILL: UNDERSTANDING NATURAL KILLER CELL LICENSING TO FIGHT CANCER

J. Schafer, 2017 .

Education‐dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells

P. Trikha, Shulin Li, Ruoning Wang, 2019, The Journal of allergy and clinical immunology.

An interactive Web site providing major histocompatibility ligand predictions: application to HIV research.

A. D. De Groot, B. Jesdale, Evan Szu, 1997, AIDS research and human retroviruses.

Activation by malaria antigens renders mononuclear cells susceptible to HIV infection and re‐activates replication of endogenous HIV in cells from HIV‐infected adults

P. Kaleebu, E. Riley, A. L. Brown, 2004, Parasite immunology.

Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia

M. Konopleva, E. Shpall, Dean Anthony Lee, 2020 .

Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.

K. Rezvani, E. Shpall, Dean Anthony Lee, 2017, Blood.

Results of a phase I trial with Haploidentical mbIL‐21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML

K. Rezvani, J. Schafer, Julianne J Chen, 2024, American journal of hematology.